FabiFlu: Glenmark launches Covid drug at Rs 103 per tablet

By: |
June 21, 2020 2:15 AM

FabiFlu is the first oral favipiravir-approved medication in India for the treatment of Covid-19, it said in a statement.

FabiFlu is the first oral favipiravir-approved medication in India for the treatment of Covid-19

Drug firm Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate Covid-19 at a price of about Rs 103 per tablet. The drug will be available as a 200 mg tablet at a maximum retail price (MRP) of Rs 3,500 for a strip of 34 tablets, Glenmark Pharmaceuticals said.

FabiFlu is the first oral favipiravir-approved medication in India for the treatment of Covid-19, it said in a statement. The tablets are being produced by the company at its Baddi facility in Himachal Pradesh. The drug will be available both through hospitals and the retail channel, Glenmark said.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Good news for COVID treatment! Antibody therapy lowers hospitalisations, emergency visits, finds study
2Lockdown Extension in India: Odisha extends lockdown in containment zones till November 31
3India’s COVID-19 caseload goes past 81 lakh with 48,648 fresh infections